Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-08-10 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT, JANUARI-JUNI 2023' (Interim Report, January-June 2023). It contains comprehensive financial statements, including income statements, cash flow summaries, and management commentary on business performance, risks, and outlook for the specified period. It is not a short announcement or a certification, but the full interim financial report itself. H1 2023
2023-08-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT – JANUARY-JUNE 2023'. It contains comprehensive financial statements, including a consolidated statement of comprehensive income, a statement of financial position, and detailed management commentary on financial performance, cash flow, and business operations for the specified period. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-08-10 English
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a short press release announcing a specific management change: the appointment of a new Chief Financial Officer (CFO), Henrik Bergentoft. This directly aligns with the definition for Board/Management Information (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The length is short (3203 chars), but the content is the announcement itself, not merely an announcement *of* an attachment, although an attachment link is present. The primary subject matter dictates the classification as MANG.
2023-08-09 English
Oncopeptides utser Henrik Bergentoft till finanschef
Board/Management Information Classification · 1% confidence The document is a press release dated August 9, 2023, announcing the appointment of Henrik Bergentoft as the new Chief Financial Officer (CFO) of Oncopeptides AB, effective in Q4. This constitutes an announcement of a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and primarily serves as an announcement, not a comprehensive report, confirming the MANG classification.
2023-08-09 Swedish
Sofia Heigis appointed CEO of Oncopeptides AB (publ)
Board/Management Information Classification · 1% confidence The document is a press release announcing a change in senior management: the current CEO is departing, and the Chief Commercial Officer (CCO) is being appointed as the new CEO, effective immediately. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. The document is short and appears to be an official announcement, not a full regulatory report like a 10-K or IR.
2023-08-07 English
Sofia Heigis utsedd till VD för Oncopeptides AB (publ)
Board/Management Information Classification · 1% confidence The document announces a change in senior management: the current CEO, Monica Shaw, is leaving, and the Chief Commercial Officer, Sofia Heigis, is taking over as the new CEO, effective immediately. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. The text is a press release format, not a full financial report (like 10-K or IR) or a transcript (CT).
2023-08-07 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.